Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Helen Boucher

Transplant/Immunocompromised States · Tufts

View

Dr. Sara Dong

Transplant/Immunocompromised States · Boston Children's Hospital

View

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Raphael J. Landovitz

HIV/AIDS Medicine · UCLA

View

Dr. Keith Kaye

General ID · RU

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Rochelle Walensky

General ID · Harvard Medical School

View

Dr. Kelly Dooley

Mycobacterial Disease · Vanderbilt

View

Dr. Erin Bonura

General ID · OHSU

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab.

    Aug 24, 2026DOI: 10.1093/cid/ciaf681Journal ArticleCID

    Written by: Nandita NadigAdarsh BhimrajKelly CawcuttKathleen ChiotosAmy L DzierbaArthur Y KimGreg S MartinJeffrey C PearsonAmy Hirsch ShumakerLindsey R BadenRoger BedimoVincent Chi-Chung ChengKara W ChewEric S DaarDavid V GliddenErica J HardySteven JohnsonChristine MacBrayneMari M NakamuraCarlos R OliveiraLaura RileyRobert W ShaferShmuel ShohamPablo TebasPhyllis C TienZachary WillisJoshua WolfJennifer LovelessYngve Falck-YtterRebecca L MorganRajesh T Gandhi

    Find these authors on Roon

    AK

    Dr. Arthur Kim

    HIV/AIDS Medicine · MGH

    SS

    Dr. Shmuel Shoham

    Transplant/Immunocompromised States · Johns Hopkins

    Summary

    This article provides a focused update to the clinical practice guideline on the treatment and management of patients with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents a new recommendation on the use of baricitinib vs. tocilizumab in hospitalized adults with severe or critical COVID-19. The panel has previously issued recommendations on baricitinib vs. no baricitinib and tocilizumab vs. no tocilizumab, but this new recommendation compares baricitinib to tocilizumab when the decision has been made to give one or the other. The new recommendation does not address combinations of multiple immunomodulatory agents (ie, baricitinib, tocilizumab, abatacept, infliximab). The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach.
    SSDr. Shmuel Shoham

    Dr. Shmuel Shoham

    Infectious Disease · Transplant/Immunocompromised States
    Johns Hopkins Medicine
    shmuel